ArticleBrazilian journal of otorhinolaryngology
The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD).
Article in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.International forum of allergy & rhinology · 2016Pooled it
- Trial
- A Narrative Review of Recent Developments in Aspirin Therapy After Desensitization in NSAIDs-Exacerbated Respiratory Disease.Journal of inflammation research · 2026Review
- Nonsteroidal anti-inflammatory drugs exacerbated respiratory disease - the role of aspirin desensitisation in patients with nasal polyposis.Postepy dermatologii i alergologii · 2022Article
- Aspirin desensitization in nonsteroidal anti-inflammatory exacerbated respiratory disease: The first prospective cohort in Chile.Frontiers in allergy · 2022Article
- Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches.Molecular biology reports · 2021Review
- Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.Iranian journal of pharmaceutical research : IJPR · 2017Article
- A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes.Laryngoscope investigative otolaryngology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAspirin-exacerbated respiratory disease (AERD) consists of a classic tetrad: moderate/severe asthma, chronic rhinosinusitis, nasal polyps, and intolerance to aspirin or other nonsteroidal anti-inflammatory drugs. Clinical control with drugs, surgery, and desensitization are treatment options.
objectiveTo evaluate the efficacy and tolerability of aspirin desensitization in patients with AERD.
methodsPeriodic symptom assessment and endoscopy in patients with AERD undergoing surgery who were desensitized.
resultsSeventeen patients were desensitized. Eight patients completed the desensitization and were followed for a minimum of a one-year period (mean 3.1 years). These patients showed improvement in all symptoms. Moreover, surgical reassessment was not indicated in any of these patients and there was a decrease in costs with medication and procedures. Eight patients did not complete desensitization, mainly due to procedure intolerance and uncontrolled asthma, whereas another patient was lost to follow-up.
conclusionAspirin desensitization, when tolerated, was effective in patients with AERD and with poor clinical/surgical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.